Form 4: Abbott Laboratories Director John G. Stratton Reports Acquisition of Stock Equivalent Units

Director John G. Stratton reports acquisition of 322 stock equivalent units in Abbott Laboratories through director fees.

Summary

• On September 30, 2024, John G. Stratton, a director of Abbott Laboratories, acquired 322 stock equivalent units.
• These units were obtained as director fees credited to a stock equivalent unit account under a grantor trust.
• The price per unit is $114.01.
• Following the transaction, Stratton beneficially owns 11,271 stock equivalent units, including those acquired through dividend reinvestment.
• These units earn the same return as if the fees were invested in Abbott shares and are generally paid in cash at age 65 or upon retirement from the board.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects a director increasing their stake in the company, indicating confidence. However, it's a routine transaction.

Positives

• The acquisition of stock equivalent units by a director signals confidence in the company's future performance.
• The director fees being reinvested into stock equivalent units aligns the director's interests with those of the shareholders.

Future Outlook

The stock equivalent units are generally paid in cash at age 65 or upon retirement from the board.

Industry Context

This filing is a routine disclosure of a director's acquisition of stock equivalent units, which is a common practice in corporate governance to align the interests of directors with those of shareholders.

Stakeholder Impact

• The acquisition of stock equivalent units by a director can positively influence shareholder confidence.

Key Dates